Uses of Enhertu (Trastuzumab Deruxtecan)

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used in the treatment of:

  • Adult patients with unresectable or metastatic HER2-positive breast cancer who have previously been treated with an anti-HER2-based agents/regimen either in the metastatic setting or in the neoadjuvant setting or adjuvant setting and have established disease recurrence during or within 6 months of completing therapy.
  • Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have previously been treated with chemotherapy in the metastatic setting or established disease recurrence during or within 6 months of completing adjuvant chemotherapy.
  • Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously been treated with the trastuzumab-based regimen.
  • Adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have previously been treated with systemic therapy.